Moolec Total Operating Expenses from 2010 to 2026
| MLEC Stock | | | 10.37 -0.11 -1.05% |
Over recent reporting cycles, Total Operating Expenses is dropping amid slightly volatile fluctuations. Compared with the previous period, Total Operating Expenses is up roughly 4.76%, supporting projections near approximately 150.3
M. Total Operating Expenses is the total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.
View All Fundamentals Total Operating Expenses | First Reported 2010-12-31 | Previous Quarter 143.2 M | Current Value 150.3 M | Quarterly Volatility 54.5 M |
Macro event markers
Credit Downgrade | Yuan Drop | Covid | Interest Hikes |
Review
Moolec Science Correlation against competitors for Moolec Science. This provides competitive positioning context.
Analyzing Moolec Science's Total Operating Expenses over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Total Operating Expenses has evolved provides context for assessing Moolec Science's current valuation and future prospects.
Latest Moolec Science's Total Operating Expenses Growth Pattern
Below is the plot of the Total Operating Expenses of Moolec Science SA over the last few years. It is the total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses. Moolec Science's Total Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moolec Science's overall financial position and show how it may be relating to other accounts over time.
| Total Operating Expenses | 10 Years Trend | | |
Moolec Total Operating Expenses Regression Statistics
| Arithmetic Mean | 25,752,009 |
| Geometric Mean | 205,614 |
| Coefficient Of Variation | 211.48 |
| Mean Deviation | 40,082,111 |
| Median | 13,802 |
| Standard Deviation | 54,461,374 |
| Sample Variance | 2966T |
| Range | 150.3M |
| R-Value | 0.69 |
| Mean Square Error | 1658.1T |
| R-Squared | 0.48 |
| Significance | 0.0022 |
| Slope | 7,440,268 |
| Total Sum of Squares | 47456.7T |
Moolec Total Operating Expenses History
| 2026 | 150.3 M | |
| 2025 | 143.2 M | |
| 2024 | 124.5 M | |
| 2023 | 9.5 M | |
| 2022 | 6.5 M | |
| 2021 | 3.7 M | |
About Moolec Science SA Ordinary Shares
Moolec Science SA is scheduled to announce its earnings today. The stock experiences an active upward rally.Moolec Science maintains listing status on the NASDAQ Exchange exchange. The profile for Moolec Science integrates fundamentals, price behavior, and sector exposure. Market-sensitive characteristics amplify cycle exposure. Moolec Science has market cap of 7.61 M, ROE of -1.75%.
Methodology
Unless otherwise specified, financial data for Moolec Science SA is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Moolec (USA Stocks:MLEC) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information for Moolec Science SA is compiled from public filings and market reference sources and official sources including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Reporting latency may occur in some cases. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Moolec Science SA is covered by 1 analyst. Representative analyst firms may include HSBC Global Research, Wells Fargo Securities, Goldman Sachs, Guggenheim Securities, RBC Capital Markets, among others. Updates may occur throughout the day.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
More Resources for Moolec Stock Analysis
A structured review of Moolec Science SA often starts with core
financial statements and trend context. Ratios and trend metrics help frame Moolec Science's operating context.
Key reports that frame Moolec Science SA Stock are listed below: Review
Moolec Science Correlation against competitors for Moolec Science. This provides competitive positioning context.
Analysis related to Moolec Science should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the
Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Earnings Share -308.81 | Revenue Per Share | Quarterly Revenue Growth 9.483 | Return On Assets | Return On Equity |
The market value of Moolec Science SA is measured differently than book value, which reflects Moolec accounting equity. Moolec Science's market capitalization is 7.61 M. A P/B ratio of 1.07 indicates the market values Moolec Science above its accounting book value. Enterprise value stands at 245.46 M. Intrinsic value is an analytical estimate of Moolec Science's underlying worth that can differ from price and book value. Valuation methods help interpret those gaps.
Note that
Moolec Science's intrinsic value and market price are different measures derived from different inputs. For Moolec Science, key inputs include a P/B ratio of 1.07, ROE of -1.75%, and revenue of 333.61 M. Market price reflects the current exchange level formed by active bids and offers.